Merck & Co., Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.merck.com

Earnings Score
Moat Score
Safety Score

Market Cap $199.39B
PE 11
Debt $34.84B
Cash $8.73B
EV $225.50B
FCF $17.04B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$17.43B
EBIT	$20.17B
ROE	36%
ROA	18%
FCF	$17.04B
Equity	$48.40B
Growth Stability	3%
PE	11.44
PEG	-2.06
PB	4.12
P/FCF	11.7
P/S	3.12
Price/Cash	0.04
Debt/Equity	0.72
Debt/FCF	2.04
Net Margins	33%
Gross Margins	76%
Op. Margins	32%
Earnings CAGR	11%
Sales Growth YoY	-2%
Sales Growth QoQ	-1%
Sales CAGR	6%
FCF CAGR	10%
Equity CAGR	1%
Earnings Stability	0.1
Earnings Growth YoY	7%
Earnings Growth QoQ	36%
Earnings CAGR 5Y	-6%

Sales CAGR 5Y	8%
FCF CAGR 5Y	22%
Equity CAGR 5Y	11%
Earnings CAGR 3Y	4%
Sales CAGR 3Y	4%
FCF CAGR 3Y	6%
Equity CAGR 3Y	1%
Market Cap	$199.39B
Revenue	$63.92B
Dividend Yield	4%
Payout Ratio	46%
Assets	$115.12B
Total Debt	$34.84B
Cash	$8.73B
Shares Outstanding	2.52B
EV	225.5B
Earnings Score	8%
Moat Score	97%
Safety Score	62%
Final Score	56%
Working Capital	10.33B
Current Ratio	1.41
Gross Profit	$48.85B
Shares Growth 3y	-0%
Equity Growth QoQ	4%
Equity Growth YoY	20%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

SEC Filings

Direct access to Merck & Co., Inc. (MRK) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Merck & Co., Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Merck & Co., Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 11%

Stability 10%

loading chart...

Merck & Co., Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Merck & Co., Inc..

Years

Calculation mode

= $330B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$17B	$19B	$20B	$22B	$25B	$27B	$29B	$32B	$35B	$39B	$42B	$424B
DCF		$17B	$17B	$17B	$17B	$17B	$17B	$17B	$16B	$16B	$16B	$164B
Value	$330B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	11%	10%	6%	15%	21%	15%	27%	24%	1%	27%	33%
ROA	-	5%	7%	11%	14%	10%	13%	15%	2%	17%	18%
ROE	-	10%	7%	23%	38%	28%	34%	32%	1%	37%	36%

Good Net Margins (32.71%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	2.84	5.35	3.02	2.64	5.71	3.82	2.09	3.84	2.05	2.04
Debt over Equity	0.59	0.62	0.71	0.93	1.01	1.25	0.87	0.67	0.93	0.8	0.72
Growth Stability	-	-	-	100%	100%	100%	100%	100%	3%	100%	3%

Neutral Debt/FCF ratio (2.04)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.72)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (3%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	1%	1%	5%	11%	2%	1%	22%	1%	7%	8%
Earnings YoY growth	-	-12%	-39%	159%	58%	-28%	85%	11%	-97%	5K%	-6%
Equity YoY growth	-	-10%	-14%	-22%	-3%	-2%	51%	20%	-18%	23%	11%
FCF YoY growth	-	-21%	-48%	82%	20%	-44%	56%	70%	-38%	98%	22%